This resource list points you to official sources where you can find verified information about Parkinson's disease treatments, recent FDA approvals, and clinical research. Whether you're newly diagnosed or managing advanced symptoms, these sources offer current treatment options, safety alerts, and trials available in your area.
NIH/NINDS oversees federal research on Parkinson's disease, which causes progressive dopamine loss in the brain, affecting ~1 million U.S. adults. Because treatment options change annually—particularly with new drug approvals and safety alerts—knowing where to check official updates directly rather than secondary sites helps you stay informed and make decisions with your neurologist.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- FDA-Approved Motor Symptom Treatments
- Current Safety Alerts—Vitamin B6 Monitoring
- Treatments Under FDA Review
- Official Sources for Current Information
- How to Use These Resources with Your Healthcare Team
- Frequently Asked Questions
FDA-Approved Motor Symptom Treatments
Levodopa (given as carbidopa/levodopa) remains the gold standard. The FDA approved carbidopa/levodopa in 1970, and it works by replacing dopamine lost in Parkinson's disease; patients typically take multiple daily doses. Newer formulations now extend dosing intervals, allowing fewer pills per day. For advanced Parkinson's with motor fluctuations—periods when medication "wears off"—two subcutaneous infusion therapies have recently arrived.
The FDA approved VYALEV (foscarbidopa/foslevodopa) on October 17, 2024, offering 24-hour continuous infusion to reduce "off" time. One month later, the FDA approved ONAPGO (apomorphine infusion) on February 4, 2025, the first U.S. apomorphine infusion therapy. It reduced daily "off" time by an average of 2.6 hours compared to 0.9 hours on placebo.
Current Safety Alerts—Vitamin B6 Monitoring
In March 2026, the FDA issued a safety alert requiring warning labels on carbidopa/levodopa products about vitamin B6 depletion and seizure risk. The alert covered 14 reported seizure cases, all in patients taking high-dose levodopa (>1,000 mg/day); seizures resolved after B6 supplementation was started.
Ask your neurologist to check your baseline B6 level before starting or increasing carbidopa/levodopa, then periodically thereafter if you take high doses. This is particularly important if you experience unusual symptoms like weakness, tingling, or confusion that could indicate deficiency.
Treatments Under FDA Review
AbbVie's tavapadon, a novel dopamine agonist taken once daily by mouth, awaits FDA decision in Q3 2026. Early trials showed it improved "on" time and delayed the need to start levodopa in early-stage disease. While not yet approved, it represents the first new oral dopamine agonist potentially arriving in over a decade if greenlit.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
Official Sources for Current Information
.
- *NIH/NINDS and NIH/NIA:** The National Institute of Neurological Disorders and Stroke (NINDS) provides peer-reviewed Parkinson's research summaries and biomarker programs, and the National Institute on Aging (NIA) maintains disease overviews and Morris K. Udall Centers information.
- *Clinical Trials:** ClinicalTrials.gov lists 139+ active Parkinson's trials searchable by phase, therapy type (symptomatic versus disease-modifying), and location. Discuss trial eligibility with your neurologist during appointments.
- *Parkinson's Foundation:** The Foundation Helpline (1-800-4PD-INFO, Mon–Fri 9 a.m.–7 p.m. ET) offers free information-specialist support, plus the Newly Diagnosed Guide, Hospital Safety Guide, and PD Health @ Home programs in English and Spanish.
How to Use These Resources with Your Healthcare Team
Start by checking NINDS or NIA for treatment overviews and recent approvals, then bring specific questions to your neurologist. If you're interested in trying a new therapy or trial, ask whether you're a candidate and whether your insurance covers it.
Use ClinicalTrials.gov to find trials near you; call or email trial sites to learn enrollment criteria. Contact Parkinson's Foundation if you need help navigating options, understanding a new diagnosis, or finding a specialist.
Frequently Asked Questions
Is levodopa still the best first-line treatment?
Yes. Carbidopa/levodopa remains the gold standard for motor symptoms across all Parkinson's stages, though newer formulations now allow fewer daily doses. Your neurologist will recommend timing and dose based on your symptoms.
Can I take vitamin B6 supplements if I'm on carbidopa/levodopa?
Ask your neurologist first, especially at high doses (>1,000 mg/day levodopa). The FDA alert advises monitoring B6 levels; supplementation should be guided by testing, not self-directed, to avoid interactions.
How do I know if I qualify for a clinical trial?
Visit ClinicalTrials.gov, search by your location and disease, and contact trial sites directly with your neurologist's medical information. Eligibility varies by trial and depends on disease stage, other medications, and other factors.
You Might Also Like
- Parkinson’s Treatment FAQ Guide: Costs Benefits Requirements and Hidden Details
- Ropinirole market entry represents significant opportunity in Parkinson’s treatment sector
- Personalized stem cell treatment for Parkinson’s: New research shows promising clinical results